secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0000950170-24-134970
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology prices $40M underwritten offering of 15.4M shares at $2.60/sh
------------------------------------------------------------------------------

- Gross proceeds ~$40M from 15,384,619 shares at $2.60 per share, before underwriting discounts.
- Net proceeds to fund onvansertib clinical costs for RAS-mutated metastatic colorectal cancer (mCRC).
- New mutual fund and healthcare dedicated investors participated; existing investors also supported.
- Expected close Dec 11, 2024; 90-day lock-up for directors and officers on share sales.
- TD Cowen lead bookrunner; William Blair, H.C. Wainwright, Craig-Hallum also underwriters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/0000950170-24-134970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/crdf-20241210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer